glp-1 updates What's next for innovation: A primer on the race reshaping pharma and chronic disease care Medicare Update: GLP-1 Medications π
Description
Early in life, these responses help maintain cellular stability, but persistent activation over time can contribute to pathology
September 30, 2025
Patients were randomly assigned to receive BYDUREON 2 mg given subcutaneously once every 7 days (weekly) or liraglutide uptitrated from 0.6 mg/day to 1.2 mg/day, then 1.8 mg/day in addition to their existing oral antidiabetic therapy
in vivo and in vitro studies
Oral options are particularly attractive for Mexico purchases because they do not require refrigeration during transport, eliminating the cold chain logistics challenge entirely
